Testing a targeted therapy after standard cancer treatment for a specific endometrial cancer type

This trial is testing whether olaparib — a targeted medication that blocks a specific protein — can help prevent endometrial cancer from coming back after you've completed standard chemotherapy and radiation. You would take this medication for one year while being closely monitored, or you could be observed without the medication. The goal is to see if the medication helps people with this particular type of endometrial cancer stay cancer-free longer.

Some endometrial cancers have a specific genetic change (called p53 abnormality) that might make them respond well to this targeted medication. Researchers want to find out whether giving this treatment for a year after standard therapy can help prevent the cancer from returning.